Form 4: Paul B. Manning Acquires 1,333,333 Shares of Taysha Gene Therapies

Paul B. Manning, a director of Taysha Gene Therapies, acquired 1,333,333 shares of common stock at $2.25 per share on June 27, 2024.

Summary

• On June 27, 2024, Paul B. Manning, a director of Taysha Gene Therapies, acquired 1,333,333 shares of the company's common stock.
• The purchase price was $2.25 per share.
• Following the transaction, Manning directly owns 1,333,333 shares.
• Manning also indirectly owns 16,566,667 shares through The Paul B. Manning Revocable Trust, 22,000 shares through BKB G2 Investments, LLC, 2,091,704 shares through BKB Growth Investments, LLC, and 4,837,407 shares through The PBM 2023 Grantor Retained Annuity Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing a significant number of shares suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's performance.

Positives

• A director's purchase of a significant number of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This transaction is a routine disclosure of insider trading activity. It's common for directors and officers to buy or sell shares of their company, and these transactions are reported to the SEC to ensure transparency.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholders, as it signals confidence from a company insider.

Key Dates